Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, multi-center, roll-over study to assess long-term safety in patients with endogenous Cushing's syndrome who have completed a prior Novartis-sponsored osilodrostat (LCI699) study and are judged by the investigator to benefit from continued treatment with osilodrostat

Trial Profile

An open-label, multi-center, roll-over study to assess long-term safety in patients with endogenous Cushing's syndrome who have completed a prior Novartis-sponsored osilodrostat (LCI699) study and are judged by the investigator to benefit from continued treatment with osilodrostat

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Feb 2019

At a glance

  • Drugs Osilodrostat (Primary)
  • Indications Cushing syndrome
  • Focus Adverse reactions
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 14 Dec 2018 Planned End Date changed from 27 Sep 2023 to 24 Oct 2023.
    • 04 Oct 2018 Planned End Date changed from 18 Jul 2023 to 27 Sep 2023.
    • 04 Oct 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top